Characteristics and Outcomes of Patients on Tofacitinib for Alopecia Areata or Rheumatoid Arthritis: A Retrospective Cohort Study

Tofacitinib is a Janus kinase inhibitor (JAKi) that is used off-label for the treatment of alopecia areata (AA). Its boxed warning includes an increased risk of serious adverse events (SAEs) based on the results of a safety trial in rheumatoid arthritis (RA) patients taking the medication. The purpo...

Full description

Bibliographic Details

Published in:	Pharmacoepidemiology
Main Authors:	Sarah Choe, Abhinav Birda, Jesse Salas, Olive Anagu, Natasha Mesinkovska
Format:	Article
Language:	English
Published:	MDPI AG 2024-01-01
Subjects:	tofacitinib JAK inhibitors alopecia alopecia areata rheumatoid arthritis adverse events
Online Access:	https://www.mdpi.com/2813-0618/3/1/3